UBAP2L and nonpapillary renal cell carcinoma: In ccRCC cells, treatment with the proteasome inhibitor MG132 significantly increased UBAP2L protein levels, while treatment with the autophagy inhibitor 3-MA had no effect on UBAP2L expression, suggesting that UBAP2L degradation occurs primarily through the UPS (Fig. 7A and S6C).